Table 2.
Individual characteristics of CKD-MBD at time of biopsya
| Patient # | Cacorr (mg/dl) | Phosphate (mg/dl) | Ca × PO4 (mg2/dl2) | iPTH (pg/ml) | CAP (pg/ml) | CIP (pg/ml) | CAP/CIP Ratio (pg2/ml2) | BS-AP (ng/ml) | Vitamin D Dose (μg)b | Binder | Biopsy Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 8.5 | 4.5 | 38 | 207.0 | 122.3 | 84.7 | 1.4 | 21.0 | 1 | CA + S | ABD |
| 2 | 9.9 | 4.0 | 40 | 40.7 | 23.9 | 16.8 | 1.4 | 14.6 | 8 | S | ABD |
| 3 | 7.8 | 3.9 | 30 | 384.1 | 267.0 | 117.1 | 2.3 | 17.3 | 0 | S | ABD |
| 4 | 8.6 | 4.7 | 40 | 301.6 | 159.4 | 142.2 | 1.1 | 12.6 | 10 | CA | ABD |
| 5 | 9.5 | 4.5 | 43 | 284.3 | 147.4 | 136.9 | 1.1 | 21.5 | 7 | S | ABD |
| 6 | 9.6 | 4.6 | 44 | 202.3 | 90.8 | 111.5 | 0.8 | 16.2 | 3 | CA | ABD |
| 7 | 9.5 | 5.9 | 56 | 157.5 | 61.2 | 96.3 | 0.6 | 12.9 | 8 | S | ABD |
| 8 | 8.3 | 6.6 | 55 | 235.0 | 158.0 | 77.0 | 2.1 | 50.8 | 3 | S | Mild HPT |
| 9 | 9.9 | 4.9 | 49 | 412.6 | 177.8 | 234.8 | 0.8 | 38.4 | 0 | S | Mild HPT |
| 10 | 7.5 | 9.6 | 72 | 380.9 | 158.0 | 222.9 | 0.7 | 23.2 | 2 | None | Mild HPT |
| 11 | 8.9 | 5.7 | 51 | 201.8 | 115.9 | 85.9 | 1.3 | 15.0 | 7 | S | Mild HPT |
| 12 | 9.9 | 4.9 | 49 | 75.1 | 41.0 | 34.1 | 1.2 | 29.0 | 6 | S | Mild HPT |
| 13 | 8.8 | 4.9 | 43 | 484.1 | 279.5 | 204.6 | 1.4 | 27.4 | 5 | S | Mild HPT |
| 14 | 9.8 | 6.2 | 61 | 2187.2 | 1248.3 | 938.9 | 1.3 | >64.0 | 3 | S | Mild HPT |
| 15 | 8.2 | 6.6 | 54 | 237.6 | 124.0 | 113.5 | 1.1 | 40.3 | 4 | S | Mild HPT |
| 16 | 9.1 | 5.4 | 49 | 1002.8 | 625.8 | 377.0 | 1.7 | >64.0 | 4 | S | Mild HPT |
| 17 | 7.9 | 5.8 | 46 | 245.0 | 149.0 | 96.0 | 1.6 | 23.2 | 1 | S | Mild HPT |
| 18 | 8.6 | 6.2 | 53 | 268.0 | 164.0 | 104.0 | 1.6 | – | 6 | S | Mild HPT |
| 19 | 8.7 | 4.7 | 41 | 784.0 | 543.0 | 241.0 | 2.0 | 54 | 2 | None | Mild HPT |
| 20 | 9.6 | 6.4 | 61 | 277.7 | 158.0 | 119.7 | 1.3 | 19.6 | 3 | CA | Mild HPT |
| 21 | 10.1 | 7.4 | 75 | 457.0 | 185.0 | 272.0 | 0.7 | 32.3 | 7 | CA + S | Mild HPT |
| 22 | 8.0 | 7.0 | 56 | 575.0 | 347.0 | 228.0 | 1.5 | 31.2 | 1 | S | Mild HPT |
| 23 | 9.5 | 5.3 | 50 | 241.0 | 147.0 | 94.0 | 1.6 | >64 | 7 | S | Moderate HPT |
| 24 | 9.5 | 6.7 | 64 | 485.9 | 271.0 | 214.9 | 1.3 | 41.8 | 5 | CA | Moderate HPT |
| 25 | 8.8 | 6.0 | 53 | 430.8 | 248.7 | 182.1 | 1.4 | 34.1 | 10 | S | Moderate HPT |
| 26 | 9.0 | 6.1 | 55 | 438.0 | 250.0 | 188.0 | 1.3 | 34.8 | 2 | CA | Moderate HPT |
| 27 | 8.3 | 5.7 | 47 | 216.0 | 141.0 | 75.0 | 1.9 | 19.1 | 3 | S | Moderate HPT |
| 28 | 8.9 | 6.3 | 56 | 408.0 | 220.0 | 188.0 | 1.2 | — | 4 | CA | Moderate HPT |
| 29 | 9.5 | 5.8 | 55 | 1105.7 | 646.5 | 459.3 | 1.4 | 62.0 | 5 | S | Moderate HPT |
| 30 | 8.9 | 4.0 | 36 | 699.0 | 404.0 | 295.0 | 1.4 | 51.5 | 3 | S | Moderate HPT |
| 31 | 9.9 | 5.7 | 56 | 649.3 | 516.8 | 132.5 | 3.9 | 23.3 | 3 | S | Moderate HPT |
| 32 | 8.5 | 5.6 | 48 | 840.0 | 447.0 | 393.0 | 1.1 | 29.1 | 5 | S | Moderate HPT |
| 33 | 8.5 | 9.2 | 78 | 1057.0 | 500.0 | 557.0 | 0.9 | 16.8 | 12 | S | Moderate HPT |
| 34 | 9.6 | 5.1 | 49 | 310.0 | 155.0 | 155.0 | 1.0 | — | 9 | CA | Moderate HPT |
| 35 | 8.8 | 9.0 | 79 | 1140.1 | 583.7 | 556.4 | 1.0 | 38.0 | 0 | S | Moderate HPT |
| 36 | 7.7 | 5.8 | 45 | 388.2 | 216.4 | 171.8 | 1.3 | 18.0 | 3 | S | Moderate HPT |
| 37 | 9.3 | 6.2 | 58 | 350.0 | 201.0 | 149.0 | 1.3 | — | 10 | S | Moderate HPT |
| 38 | 9.0 | 5.9 | 53 | 961.7 | 530.5 | 431.2 | 1.2 | 52.2 | 8 | CA | Moderate HPT |
| 39 | 9.2 | 7.1 | 65 | 755.8 | 528.0 | 227.0 | 2.3 | 63.8 | 6 | CA | Severe HPT |
| 40 | 9.2 | 6.0 | 55 | 1110.3 | 516.8 | 593.6 | 0.9 | >64 | 3 | CA | Severe HPT |
| 41 | 8.9 | 7.9 | 70 | 941.4 | 434.5 | 506.9 | 0.9 | >64 | 3 | none | Severe HPT |
| 42 | 9.8 | 4.8 | 47 | 1316.6 | 590.6 | 726.0 | 0.8 | >64 | 3 | S | Severe HPT |
| 43 | 10.0 | 7.5 | 75 | 752.0 | 598.0 | 154.0 | 3.9 | 46.1 | 3 | S | Severe HPT |
a
CAP, cyclase activating parathyroid hormone (PTH); CIP, cyclase inactive PTH; Ca × PO4, calcium-phosphorous product; BS-AP, bone-specific alkaline phosphatase; S, sevelamer; CA, calcium acetate.
b
Vitamin D exposure reported as microgram per treatment.